Cantor Fitzgerald analyst reiterated an Overweight rating on Zealand Pharma A/S (NASDAQ: ZEAL).The analyst commented, “We updated our model for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE